Pharma Stocks
-
Costco’s Healthcare Move Turns Heads. We’re Buying These Pharma Stocks Instead.
According to a report in the Wall Street Journal, Costco (COST) is about to launch its own Medicare Advantage plan…
Read More » -
Amylyx Pharmaceuticals (AMLX) Is Up 48.6% After Positive Phase 3 Avexitide Data And $350M Equity Raise – Has The Bull Case Changed?
In August 2026, Amylyx Pharmaceuticals reported positive topline Phase 3 LUCIDITY results showing avexitide significantly reduced serious hypoglycemic events in…
Read More » -
Why Eli Lilly (LLY) Stock Is Up Today
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the company announced…
Read More » -
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
Kailera Therapeutics (NASDAQ:KLRA) closed most recently at $18.51, between a post-IPO high of $28.23 and low of $16.39, with a…
Read More » -
Crinetics Pharmaceuticals (CRNX) Stock Looks Overvalued Despite Strong 3 Year Returns
Crinetics Pharmaceuticals has delivered a very strong share price run over the past three years, yet its current valuation screens…
Read More » -
NATCO Pharma Limited Recorded A 5.3% Miss On Revenue: Analysts Are Revisiting Their Models
NATCO Pharma Limited (NSE:NATCOPHARM) shareholders are probably feeling a little disappointed, since its shares fell 2.3% to ₹890 in the…
Read More » -
Why Isn’t Eli Lilly Stock Trading At The Top Of Its Peer Group?
The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group’s fastest-growing performers…
Read More » -
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma – August 17, 2026
Key Takeaways RXRX uses AI, biological data and automation, while SDGR combines physics-based modeling with AI. RLAY uses protein-motion technology…
Read More » -
NATCO Pharma Limited (NSE:NATCOPHARM) Looks Like A Good Stock, And It’s Going Ex-Dividend Soon
NATCO Pharma Limited (NSE:NATCOPHARM) stock is about to trade ex-dividend in two days. The ex-dividend date is commonly two business…
Read More » -
Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales Guidance – And What’s Next
Tarsus Pharmaceuticals, Inc. reported past second-quarter 2026 results showing revenue of US$173.91 million versus US$102.66 million a year earlier, with…
Read More »